A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 5,665 shares of REGN stock, worth $5.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,665
Previous 5,814 2.56%
Holding current value
$5.93 Million
Previous $5.6 Million 6.42%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$883.2 - $1071.19 $131,596 - $159,607
-149 Reduced 2.56%
5,665 $5.95 Million
Q1 2024

May 09, 2024

BUY
$902.69 - $993.35 $173,316 - $190,723
192 Added 3.42%
5,814 $5.6 Million
Q4 2023

Mar 05, 2024

SELL
$775.18 - $881.7 $10,077 - $11,462
-13 Reduced 0.23%
5,622 $4.94 Million
Q4 2023

Feb 06, 2024

BUY
$775.18 - $881.7 $375,962 - $427,624
485 Added 9.42%
5,635 $4.95 Million
Q3 2023

Nov 13, 2023

SELL
$692.45 - $844.37 $150,954 - $184,072
-218 Reduced 4.06%
5,150 $4.24 Million
Q2 2023

Dec 12, 2023

BUY
$700.03 - $830.35 $152,606 - $181,016
218 Added 4.23%
5,368 $3.86 Million
Q2 2023

Aug 08, 2023

BUY
$700.03 - $830.35 $484,420 - $574,602
692 Added 14.8%
5,368 $3.86 Million
Q1 2023

Dec 12, 2023

SELL
$680.49 - $826.97 $532,823 - $647,517
-783 Reduced 15.2%
4,367 $3.59 Million
Q1 2023

May 01, 2023

BUY
$680.49 - $826.97 $47,634 - $57,887
70 Added 1.52%
4,676 $3.84 Million
Q4 2022

Feb 03, 2023

SELL
$705.89 - $766.39 $9,176 - $9,963
-13 Reduced 0.28%
4,606 $3.32 Million
Q3 2022

Nov 08, 2022

BUY
$573.97 - $724.32 $28,698 - $36,216
50 Added 1.09%
4,619 $3.18 Million
Q2 2022

Aug 09, 2022

BUY
$548.35 - $738.84 $1,645 - $2,216
3 Added 0.07%
4,569 $2.7 Million
Q1 2022

May 05, 2022

SELL
$595.12 - $698.43 $386,828 - $453,979
-650 Reduced 12.46%
4,566 $3.19 Million
Q4 2021

Feb 02, 2022

BUY
$543.48 - $670.97 $77,174 - $95,277
142 Added 2.8%
5,216 $3.29 Million
Q3 2021

Oct 26, 2021

SELL
$574.03 - $680.96 $48,792 - $57,881
-85 Reduced 1.65%
5,074 $3.07 Million
Q2 2021

Jul 27, 2021

BUY
$472.8 - $558.54 $20,803 - $24,575
44 Added 0.86%
5,159 $2.88 Million
Q1 2021

Apr 27, 2021

SELL
$446.73 - $548.2 $50,033 - $61,398
-112 Reduced 2.14%
5,115 $2.42 Million
Q4 2020

Jan 29, 2021

SELL
$478.3 - $607.98 $21,045 - $26,751
-44 Reduced 0.83%
5,227 $2.53 Million
Q3 2020

Nov 10, 2020

BUY
$544.75 - $658.21 $70,817 - $85,567
130 Added 2.53%
5,271 $2.95 Million
Q2 2020

Aug 07, 2020

SELL
$493.32 - $643.92 $986 - $1,287
-2 Reduced 0.04%
5,141 $3.21 Million
Q1 2020

Apr 28, 2020

SELL
$336.18 - $494.43 $48,746 - $71,692
-145 Reduced 2.74%
5,143 $2.51 Million
Q4 2019

Feb 12, 2020

SELL
$274.13 - $376.51 $43,586 - $59,865
-159 Reduced 2.92%
5,288 $1.99 Million
Q3 2019

Oct 29, 2019

BUY
$273.46 - $318.39 $4,922 - $5,731
18 Added 0.33%
5,447 $1.51 Million
Q2 2019

Jul 30, 2019

SELL
$299.6 - $414.82 $29,660 - $41,067
-99 Reduced 1.79%
5,429 $1.7 Million
Q1 2019

Apr 22, 2019

BUY
$372.08 - $439.57 $1.59 Million - $1.87 Million
4,264 Added 337.34%
5,528 $2.27 Million
Q4 2018

Jan 25, 2019

SELL
$335.82 - $403.04 $4,701 - $5,642
-14 Reduced 1.1%
1,264 $472,000
Q3 2018

Oct 24, 2018

SELL
$351.14 - $408.51 $106,044 - $123,370
-302 Reduced 19.11%
1,278 $516,000
Q2 2018

Jul 09, 2018

BUY
$284.6 - $344.99 $71,150 - $86,247
250 Added 18.8%
1,580 $545,000
Q1 2018

May 11, 2018

SELL
$315.82 - $393.78 $83,692 - $104,351
-265 Reduced 16.61%
1,330 $458,000
Q1 2018

Apr 19, 2018

BUY
$315.82 - $393.78 $41,056 - $51,191
130 Added 8.87%
1,595 $549,000
Q4 2017

Jan 24, 2018

SELL
$358.63 - $469.95 $39,090 - $51,224
-109 Reduced 6.93%
1,465 $551,000
Q3 2017

Oct 17, 2017

BUY
$431.38 - $504.0 $678,992 - $793,296
1,574
1,574 $704,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $112B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.